On September 27th, “Promotion Meeting for the Three-Year Initiative of The Province’s Trademark Strategy” co-hosted by the Leading Group Office of Jiangsu Trademark Strategy Implementation Work and Provincial Administration for Industry & Commerce was held as scheduled in Nanjing.
At the meeting, awards were presented to municipalities, counties and enterprises that made contribution to the province for their outstanding achievements in brand building. Hansoh Pharma Group was granted the title of “Model Enterprise for the Implementation of Jiangsu Trademark Strategy (the Golden Sail Award)”.
Major selection criteria of “Golden Sail Award” include enterprise’s publicity and reputation, awareness of trademark protection, market competitiveness, innovation ability, influence, credit and CSR. Being granted the title of “Model Enterprise for the Implementation of Jiangsu Trademark Strategy” indicates that Hansoh is at provincial forefront among its peers in terms of brand strategy, brand management, and brand implementation.
As a domestic leading innovative pharmaceutical group, Hansoh Pharma implements decisions and plans formulated by CPC Central Committee, the State Council, the provincial party committee and the provincial government. It constantly strengthens brand building of its trademarks, gives full play to the important role of brands in leading innovation and driving transformation, and contributes its efforts to advancing supply-side reform. Hansoh has achieved remarkable results in brand building. It has almost 10 provincial and 20 municipal-wide well-known trademarks.
Besides brand building, Hansoh has also achieved remarkable results in brand implementation including technology innovation, quality excellence, integrity and CSR.
The Hansoh brand has long been enjoying a nationwide reputation. The Company is a national model enterprise for technological innovation and intellectual property. Its innovation ability ranks among the top 3 in the industry. It has undertaken more than 20 national major science and technology projects. The first Category 1.1 new drug “Mailingda” (Morinidazole and Sodium Chloride Injection), the only domestic nitroimidazole drug with entire independent intellectual property right, was launched in 2014. Key products “Zefei” and “Oulanning” won the 2013 and 2014 National Science and Technology Major Project award respectively.
In terms of quality, Hansoh has set up a quality management system of international first-class standards. Its API acquired US FDA approval in 2003, oncology injection Zefei and Gainuo acquired the approval in 2012 and successfully entered developed markets of Europe and the US. Hansoh was granted the title of “China’s leading pharmaceutical enterprise in internationalization of pharmaceutical products”.
Hansoh adheres to the corporate mission of “serving the society and creating a healthy world”. It is at the forefront of domestic peers in terms of corporate integrity and CSR. The company is a national “Contract-honoring and Credit-respecting Enterprise” and “National Model Enterprise for Integrity in Drug Quality”. It takes the initiative to undertake social responsibilities and carried out public welfare activities such as providing assistance to doctors, students, the poor, and disaster relief. It has also established a special NPO - Huilan Public Welfare, committed to the development of China’s pharmaceutical industry. A large number of high-quality medicines such as Oulanning, Zefei, and Xinwei have successfully helped millions of patients return to healthy life at a low cost of treatment, contributing to maintaining national health security and reducing financial pressure from medical care.
In the context of national policies such as “Healthy China 2030” and “Made in China 2025”, Hansoh Pharma will focus on technological innovation and strive to realize the corporate vision of “becoming a world first-class innovative pharmaceutical company”, contributing its strengths to the internationalization of domestic pharmaceutical brands, the realization of the overall goal of " innovating and creating wealth for a high-level well-off society", and the building of a new Jiangsu that is wealthy, beautiful and civilized.
